

Offer oncologist-hematologists consistency in CML monitoring
BCR::ABL1 Mbcr fusion gene clinical research
When CML research applications require the quantitative detection of BCR::ABL1 Mbcr e14a2 (b3a2) & e13a2 (b2a2)fusion gene transcripts on the IS, our BCR-ABL1 Mbcr RGQ RT-PCR and ipsogen BCR-ABL1 Mbcr IS-MMR kits will deliver.
Browse our region-specific BCR::ABL1 Mbcr tests
BCR-ABL1 Mbcr RGQ RT-PCR Kit
For the quantification of BCR-ABL1 Mbcr b3a2 and b2a2 fusion gene transcripts, results alignment on the international scale, MMR and MR4.5 reporting
ipsogen BCR-ABL1 Mbcr IS-MMR Kits
For the quantification of BCR-ABL1 Mbcr b3a2 & b2a2 fusion gene transcripts and results alignment on the international scale
In line with established HUGO Gene Nomenclature Committee (HGNC) recommendations for the fusion gene nomenclature (Bruford EA, et al. Leukemia. 2021, https://doi.org/10.1038/s41375-021-01436-6), we are implementing use of italics and double colon (::) for fusion genes designation (e.g. BCR::ABL1). However historical nomenclature (e.g. BCR-ABL1) may persist in our materials.